Cargando…

Actual status of veralipride use

During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride ha...

Descripción completa

Detalles Bibliográficos
Autor principal: Carranza-Lira, Sebastián
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938034/
https://www.ncbi.nlm.nih.gov/pubmed/20852674
_version_ 1782186565244551168
author Carranza-Lira, Sebastián
author_facet Carranza-Lira, Sebastián
author_sort Carranza-Lira, Sebastián
collection PubMed
description During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules.
format Text
id pubmed-2938034
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29380342010-09-17 Actual status of veralipride use Carranza-Lira, Sebastián Clin Interv Aging Review During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules. Dove Medical Press 2010 2010-09-07 /pmc/articles/PMC2938034/ /pubmed/20852674 Text en © 2010 Carranza-Lira, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Carranza-Lira, Sebastián
Actual status of veralipride use
title Actual status of veralipride use
title_full Actual status of veralipride use
title_fullStr Actual status of veralipride use
title_full_unstemmed Actual status of veralipride use
title_short Actual status of veralipride use
title_sort actual status of veralipride use
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938034/
https://www.ncbi.nlm.nih.gov/pubmed/20852674
work_keys_str_mv AT carranzalirasebastian actualstatusofveraliprideuse